Plus Products Competitors

Plus Products (OTCMKTS:PLPRF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Plus Products and Abacus Health Products' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Plus Products and Abacus Health Products, as reported by MarketBeat.com.

Plus Products currently has a consensus price target of $1.50, suggesting a potential upside of 188.46%. Given Plus Products' higher possible upside, equities analysts plainly believe Plus Products is more favorable than Abacus Health Products.

Profitability

This table compares Plus Products and Abacus Health Products' net margins, return on equity and return on assets.

Summary

Plus Products beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

Plus Products (OTCMKTS:PLPRF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Plus Products and Acreage's top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Plus Products and Acreage, as reported by MarketBeat.com.

Plus Products currently has a consensus price target of $1.50, suggesting a potential upside of 188.46%. Acreage has a consensus price target of $8.4333, suggesting a potential upside of 204.45%. Given Acreage's higher possible upside, analysts plainly believe Acreage is more favorable than Plus Products.

Profitability

This table compares Plus Products and Acreage's net margins, return on equity and return on assets.

Summary

Acreage beats Plus Products on 2 of the 3 factors compared between the two stocks.

Plus Products (OTCMKTS:PLPRF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Plus Products and Applied Biosciences' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Plus Products and Applied Biosciences, as reported by MarketBeat.com.

Plus Products currently has a consensus price target of $1.50, suggesting a potential upside of 188.46%. Given Plus Products' higher possible upside, equities analysts plainly believe Plus Products is more favorable than Applied Biosciences.

Profitability

This table compares Plus Products and Applied Biosciences' net margins, return on equity and return on assets.

Summary

Plus Products beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Plus Products (OTCMKTS:PLPRF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Plus Products and Ayr Strategies' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Plus Products and Ayr Strategies, as reported by MarketBeat.com.

Plus Products currently has a consensus price target of $1.50, suggesting a potential upside of 188.46%. Ayr Strategies has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Given Plus Products' stronger consensus rating and higher possible upside, equities analysts plainly believe Plus Products is more favorable than Ayr Strategies.

Profitability

This table compares Plus Products and Ayr Strategies' net margins, return on equity and return on assets.

Summary

Plus Products beats Ayr Strategies on 2 of the 3 factors compared between the two stocks.

Plus Products (OTCMKTS:PLPRF) and Can B (NASDAQ:CANB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Plus Products and Can B's top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Plus Products and Can B, as reported by MarketBeat.com.

Plus Products currently has a consensus price target of $1.50, suggesting a potential upside of 188.46%. Given Plus Products' higher possible upside, equities analysts plainly believe Plus Products is more favorable than Can B.

Profitability

This table compares Plus Products and Can B's net margins, return on equity and return on assets.

Summary

Plus Products beats Can B on 2 of the 2 factors compared between the two stocks.

Plus Products (OTCMKTS:PLPRF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Valuation and Earnings

This table compares Plus Products and Cansortium's top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Plus Products and Cansortium, as reported by MarketBeat.

Plus Products currently has a consensus price target of $1.50, suggesting a potential upside of 188.46%. Cansortium has a consensus price target of $1.20, suggesting a potential upside of 18.81%. Given Plus Products' higher possible upside, research analysts clearly believe Plus Products is more favorable than Cansortium.

Profitability

This table compares Plus Products and Cansortium's net margins, return on equity and return on assets.

Summary

Plus Products beats Cansortium on 1 of the 1 factors compared between the two stocks.